Inmagene Biopharmaceuticals merges with Ikena Oncology, forming ImageneBio, Inc. The company will trade on Nasdaq under the ticker symbol “IMA” starting July 28, 2025. ImageneBio will continue Phase 2b clinical trial of anti-OX40 antibody IMG-007 for atopic dermatitis, with topline results expected in Q4 2026. A $75 million private placement was completed with investors like Deep Track Capital and Foresite Capital. ImageneBio aims to develop treatments for immunological diseases, led by CEO Dr. Kristin Yarema. Reverse stock split and equity distribution details were also provided. Shares to trade under new CUSIP number 45175G 207.

Read more at GlobeNewswire: Inmagene Biopharmaceuticals Announces Completion of Merger